Sarepta Q1 net income swings to USD 331 million; revenue slips 2% to USD 730.8 million

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

SRPT

0.00
  • Sarepta Therapeutics swung to net income of USD 330.96 million, or USD 3.15 per share, as operating income totaled USD 358.43 million.
  • Revenue dipped 2% to USD 730.8 million as product sales slid 46% to USD 330.52 million.
  • ELEVIDYS revenue dropped 73% to USD 101.97 million, while PMO products eased 3% to USD 228.55 million.
  • Collaboration and other revenue climbed to USD 400.29 million, including USD 365 million tied to Roche’s declined option and USD 40 million milestone for first commercial dosing of ELEVIDYS in Japan.
  • Research and development expense fell 80% to USD 153.96 million, while cash, cash equivalents, restricted cash and investments totaled USD 748.25 million at March 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-208893), on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.